226 related articles for article (PubMed ID: 21482982)
41. FDG PET and PET/CT in the Management of Pediatric Lymphoma Patients.
Cheng G; Servaes S; Alavi A; Zhuang H
PET Clin; 2008 Oct; 3(4):621-34. PubMed ID: 27156825
[TBL] [Abstract][Full Text] [Related]
42. Update on pediatric leukemia and lymphoma imaging.
Averill LW; Acikgoz G; Miller RE; Kandula VV; Epelman M
Semin Ultrasound CT MR; 2013 Dec; 34(6):578-99. PubMed ID: 24332209
[TBL] [Abstract][Full Text] [Related]
43. FDG PET and high-dose therapy for aggressive lymphomas: toward a risk-adapted strategy.
Kasamon YL; Wahl RL; Swinnen LJ
Curr Opin Oncol; 2004 Mar; 16(2):100-5. PubMed ID: 15075899
[TBL] [Abstract][Full Text] [Related]
44. Can diffusion-weighed whole-body magnetic resonance imaging with body signal suppression play a role in the management of lymphoma patients?
Minoia C; Maggialetti N; Ferrari C; Brunese L; Rubini G; Guarini A
J BUON; 2016; 21(1):282-3. PubMed ID: 27061563
[No Abstract] [Full Text] [Related]
45. Dynamic infrared imaging of newly diagnosed malignant lymphoma compared with Gallium-67 and Fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography.
Janicek MJ; Demetri G; Janicek MR; Shaffer K; Fauci MA
Technol Cancer Res Treat; 2003 Dec; 2(6):571-8. PubMed ID: 14640768
[TBL] [Abstract][Full Text] [Related]
46. The Use of PET in Radiation Therapy for Lymphoma.
Plastaras JP; Geiger G; Perini R; Glatstein E
PET Clin; 2012 Jan; 7(1):67-72. PubMed ID: 27157019
[TBL] [Abstract][Full Text] [Related]
47. Prognostication and Risk-Adapted Therapy of Hodgkin's Lymphoma Using Positron Emission Tomography.
Kasamon YL
Adv Hematol; 2011; 2011():271595. PubMed ID: 21253532
[TBL] [Abstract][Full Text] [Related]
48. Lymphoma imaging: nuclear medicine.
Kostakoglu L; Goldsmith SJ
Cancer Treat Res; 2006; 131():363-412. PubMed ID: 16704177
[No Abstract] [Full Text] [Related]
49. Role of Positron Emission Tomography with Fludeoxyglucose F 18 in Personalization of Therapy in Patients with Lymphoma.
Mato AR; Goy A
PET Clin; 2012 Jan; 7(1):57-65. PubMed ID: 27157018
[TBL] [Abstract][Full Text] [Related]
50. Evolving role of positron emission tomography (PET) in urological malignancy.
Mafeld S; Vasdev N; Patel A; Ali T; Lane T; Boustead G; Thorpe AC; Adshead JM; Haslam P
BJU Int; 2015 Oct; 116(4):538-45. PubMed ID: 25410715
[TBL] [Abstract][Full Text] [Related]
51. Present state and future role of gallium-67 scintigraphy in lymphoma.
Front D; Israel O
J Nucl Med; 1996 Mar; 37(3):530-2. PubMed ID: 8772660
[No Abstract] [Full Text] [Related]
52. The role of computed tomography and other imaging modalities in malignant lymphoma.
Rickard MT
Australas Radiol; 1984 May; 28(2):140-7. PubMed ID: 6393939
[No Abstract] [Full Text] [Related]
53. Role of routine imaging in lymphoma.
Wagner-Johnston ND; Bartlett NL
J Natl Compr Canc Netw; 2011 May; 9(5):575-84; quiz 585. PubMed ID: 21550970
[TBL] [Abstract][Full Text] [Related]
54. Unproven value of end-of-treatment and serial follow-up FDG-PET in primary mediastinal B-cell lymphoma.
Adams HJA; Kwee TC
Haematologica; 2018 Aug; 103(8):e380-e381. PubMed ID: 30065019
[No Abstract] [Full Text] [Related]
55. Surveillance imaging for lymphoma: pros and cons.
Lynch RC; Zelenetz AD; Armitage JO; Carson KR
Am Soc Clin Oncol Educ Book; 2014; ():e388-95. PubMed ID: 24857129
[TBL] [Abstract][Full Text] [Related]
56. [Conventional nuclear medicine in the diagnosis and evaluation of hematologic neoplasma (lymphomas)].
Martín Curto LM; García Vicente AM; Rodado Marina S; Marín Ferrer MD; Coya Viña J
Sangre (Barc); 1997 Aug; 42(4):309-14. PubMed ID: 9381288
[No Abstract] [Full Text] [Related]
57. Imaging guiding therapy development in lymphoma.
Link BK
Clin Pharmacol Ther; 2008 Oct; 84(4):443-5. PubMed ID: 18802425
[TBL] [Abstract][Full Text] [Related]
58. Monitoring lymphoma patients after therapy.
Roschewski M
Clin Adv Hematol Oncol; 2015 May; 13(5):277-9. PubMed ID: 26352768
[No Abstract] [Full Text] [Related]
59. Evolution of lymphoma staging and response evaluation: current limitations and future directions.
Cunningham J; Iyengar S; Sharma B
Nat Rev Clin Oncol; 2017 Oct; 14(10):631-645. PubMed ID: 28607514
[TBL] [Abstract][Full Text] [Related]
60. Monitoring response in lymphomas: qualitative, quantitative, or what else?
Biggi A; Bergesio F; Chauvie S
Leuk Lymphoma; 2019 Feb; 60(2):302-308. PubMed ID: 30033835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
